Gilead Sciences and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170926005682/en/
On
With the expiration of the waiting period, the tender offer is expected
to close in the beginning of
About Kite
Kite is a biopharmaceutical company engaged in the development of
innovative cancer immunotherapies with a goal of providing rapid,
long-term, durable response and eliminating the burden of chronic care.
The company is focused on chimeric antigen receptor (CAR) and T cell
receptor (TCR) engineered cell therapies designed to empower the immune
system's ability to recognize and kill tumors. On
About
Forward-Looking Statements
This press release includes forward-looking statements that are subject
to risks, uncertainties and other factors. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements, including all statements regarding the
intent, belief or current expectation of the companies and members of
their senior management teams. Forward-looking statements include,
without limitation, statements regarding the business combination; its
effect on Gilead's revenues and earnings; the commercial success of
Kite's products; approval of axi-cel by regulatory authorities; the
ability of Gilead to advance Kite's product pipeline, including axi-cel;
the anticipated timing of clinical data; the possibility of unfavorable
results from clinical trials; filings and approvals relating to the
transaction; the expected timing of the completion of the transaction;
the ability to complete the transaction considering the various closing
conditions; difficulties or unanticipated expenses in connection with
integrating the companies; and the accuracy of any assumptions
underlying any of the foregoing. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties and are cautioned not to place undue
reliance on these forward-looking statements. Actual results may differ
materially from those currently anticipated due to a number of risks and
uncertainties. Risks and uncertainties that could cause the actual
results to differ from expectations contemplated by forward-looking
statements include: uncertainties as to the timing of the tender offer
and merger; uncertainties as to how many of Kite's stockholders will
tender their stock in the offer; the possibility that competing offers
will be made; the possibility that various closing conditions for the
transaction may not be satisfied or waived; the effects of the
transaction on relationships with employees, customers, other business
partners or governmental entities; other business effects, including the
effects of industry, economic or political conditions outside of the
companies' control; transaction costs; actual or contingent liabilities;
and other risks and uncertainties detailed from time to time in the
companies' periodic reports filed with the
Additional Information and Where to Find It
This announcement is neither an offer to purchase nor a solicitation of
an offer to sell shares of Kite. A solicitation and an offer to buy
shares of Kite have been made pursuant to an offer to purchase and
related materials, as amended and supplemented from time to time, that
Gilead filed with the
For more information on
View source version on businesswire.com: http://www.businesswire.com/news/home/20170926005682/en/
Investors
or
Media
or
Investors
& Media
Source:
News Provided by Acquire Media